Fig. 2From: Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trialsAssociation of durable response with (a) FACT-BRM domain and subscale improvement and (b) TOI Improvement. aAnalysis was limited to patients with tumor assessments ≥9 months evaluable for improvement. bOdds ratio stratified by disease stage and lines of therapy. cOnly patients followed up for ≥9 months included. DR durable response, FACT-BRM Functional Assessment of Cancer Therapy Biologic Response Modifier, HR hazard ratio, TOI Trial Outcome IndexBack to article page